Live Webinar: Time to RSVP to RSV Prevention: Severe RSV Disease Burden and the Evidence Supporting RSV Vaccination and Monoclonal Antibodies (09/23/2026)
This is a live webinar on Sept 23, 2026 at 1 pm ET.
Please enroll to complete demographic questions, pre-assessment, and register through GoToWebinar.
Respiratory syncytial virus (RSV) has a high burden of disease in infants as well as older adults and adults with certain risk factors. RSV can lead to severe disease, causing hospitalization and death in these populations. There have been many recent advancements in RSV disease prevention including vaccines for older adults, adults with certain risk factors, and pregnant women as well as passive immunization with monoclonal antibodies for infants and young children. Pharmacists must be aware of the full burden of disease in these patient populations and the clinical evidence supporting the use of vaccines and monoclonal antibodies to protect patients against the risk of severe RSV disease. This educational activity will use case-based examples to show the range of RSV-related diseases including the burden of hospitalization and severe cases for infants. This activity will also discuss the burden of RSV disease in adults along with risk factors for severe RSV disease including age, comorbidities, and social determinants of health. The mechanism of action, safety, efficacy, and characteristics of RSV monoclonal antibodies and vaccines will be examined, as well as methods to apply the current clinical data and real-world evidence to improve patient care and ensure patients are appropriately immunized.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
This activity was planned to meet the educational needs of pharmacists who practice in hospitals, health systems, ambulatory clinics, and community settings who provide immunizations.
At the conclusion of this activity, participants should be able to:
Identify patients who may be at higher risk for developing severe RSV disease.
Analyze the clinical evidence of RSV vaccines and monoclonal antibodies including the mechanism of action, safety, efficacy, and their different characteristics.
Monica V. Mahoney, PharmD, BCPS, BCIDP, FCCP, FIDSA, FIDP, FMSHP Activity Chair Clinical Pharmacy Specialist – Infectious Diseases Beth Israel Deaconess Medical Center Boston, Massachusetts
Monica Mahoney, PharmD, BCPS, BCIDP, FCCP, FIDSA, FIDP, FMSHP is a clinical pharmacy specialist in the outpatient infectious diseases and outpatient parenteral antibiotic therapy (OPAT) clinics at Beth Israel Deaconess Medical Center in Boston, MA. Dr. Mahoney received her PharmD degree from MCPHS University in Boston, Massachusetts. She completed postgraduate year 1 residency and postgraduate year 2 infectious diseases residency at Tufts Medical Center in Boston, Massachusetts. She is an active member of many pharmacy and infectious diseases professional organizations, including ASHP, the Society of Infectious Diseases Pharmacists, the Infectious Diseases Society of America, and the Society for Healthcare Epidemiology of America. She is an associate editor at Open Forum Infectious Diseases (OFID), section editor at Contagion Live, and on the editorial board for Antimicrobial Stewardship & Hospital Epidemiology (ASHE).
Sarah Parsons, PharmD, BCPPS, FPPA Clinical Pharmacy Specialist; Pediatric Infectious Diseases Antimicrobial Stewardship Co-Lead The Children's Hospital of The King's Daughters Norfolk, Virginia
Sarah Parsons, PharmD, BCPPS, FPPA is a clinical pharmacy specialist in pediatric infectious diseases and the co-lead of the antimicrobial stewardship program at the Children’s Hospital of The King’s Daughters. Dr. Parsons received her Doctor of Pharmacy Degree from Virginia Commonwealth School of Pharmacy. She completed a PGY1 with pediatric focus at HCA Health system in Richmond, Virginia. Dr. Parsons specializes in the treatment of multi-drug resistant gram negative infections, nontuberculous mycobacterium in cystic fibrosis, COVID/MIS-C, and vaccine preventable diseases in children. She is an active member of many pharmacy, pediatric, and infectious diseases professional organizations, including ASHP, the Pediatric Infectious Diseases Society, the Society of Infectious Diseases Pharmacists, the American College of Clinical Pharmacy, and is a 2025 fellow of the Pediatric Pharmacy Association.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
Monica Mahoney: Consultant – CSL Seqirus
All other persons in control of content do not have any relevant financial relationships with an ineligible company.
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.
To receive CE credit, complete the steps below within 60 days of completing the activity.
Complete the pre-assessment during webinar registration
Attend the live webinar
Answer all post-assessment questions
Complete the evaluation and claim credit
Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.
Important Note – ACPE 60 Day Deadline Per ACPE requirements, CPE credit must be claimed within 60 days of being earned – no exceptions! To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, we encourage you to check your NABP eProfile account to validate your credits were transferred successfully before the ACPE 60-day deadline. After the 60 day deadline, ASHP will no longer be able to award credit for this activity.
